Pharmac is seeking feedback on a proposal to fund another brand of methylphenidate – Rubifen LA – to help ease ongoing supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD).

If approved, this brand would be funded from 1 July 2026.  

Proposal to fund a new brand of methylphenidate (pharmac.govt.nz) 

Consultation is open until 5pm, 4 December 2025

Pharmac welcomes your feedback, which can be sent to consult@pharmac.govt.nz or through the online form linked in the consultation document.

Article added: Thursday 20 November 2025